- Home
- LYEL vs CRDF Comparison
LYEL vs CRDF Comparison
Compare LYEL & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- CRDF
- Stock Information
- Founded
- LYEL 2018
- CRDF 1999
- Country
- LYEL United States
- CRDF United States
- Employees
- LYEL N/A
- CRDF N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LYEL Health Care
- CRDF Health Care
- Exchange
- LYEL Nasdaq
- CRDF Nasdaq
- Market Cap
- LYEL 207.7M
- CRDF 169.6M
- IPO Year
- LYEL 2021
- CRDF N/A
- Fundamental
- Price
- LYEL $0.44
- CRDF $3.35
- Analyst Decision
- LYEL Sell
- CRDF Strong Buy
- Analyst Count
- LYEL 2
- CRDF 4
- Target Price
- LYEL $1.00
- CRDF $12.25
- AVG Volume (30 Days)
- LYEL 627.4K
- CRDF 839.8K
- Earning Date
- LYEL 05-13-2025
- CRDF 05-08-2025
- Dividend Yield
- LYEL N/A
- CRDF N/A
- EPS Growth
- LYEL N/A
- CRDF N/A
- EPS
- LYEL N/A
- CRDF N/A
- Revenue
- LYEL $65,000.00
- CRDF $587,000.00
- Revenue This Year
- LYEL N/A
- CRDF N/A
- Revenue Next Year
- LYEL N/A
- CRDF N/A
- P/E Ratio
- LYEL N/A
- CRDF N/A
- Revenue Growth
- LYEL N/A
- CRDF N/A
- 52 Week Low
- LYEL $0.39
- CRDF $2.01
- 52 Week High
- LYEL $2.80
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- LYEL 51.63
- CRDF 63.72
- Support Level
- LYEL $0.39
- CRDF $2.81
- Resistance Level
- LYEL $0.43
- CRDF $3.43
- Average True Range (ATR)
- LYEL 0.03
- CRDF 0.19
- MACD
- LYEL 0.00
- CRDF 0.08
- Stochastic Oscillator
- LYEL 83.39
- CRDF 85.54
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.